TLD-1, a novel liposomal doxorubicin, in patients with advanced solid tumors: Dose escalation and expansion part of a multicenter open-label phase I trial (SAKK 65/16)

Autor: Colombo, Ilaria, Koster, Kira-Lee, Holer, Lisa, Haefliger, Simon, Rabaglio, Manuela, Bastian, Sara, Schwitter, Michael, Eckhardt, Katrin, Hayoz, Stefanie, Mc Laughlin, Anna M., Kloft, Charlotte, Klose, Marian, Halbherr, Stefan, Baumgartner, Christian, Sessa, Cristiana, Stathis, Anastasios, Hess, Dagmar, Joerger, Markus
Zdroj: In European Journal of Cancer April 2024 201
Databáze: ScienceDirect
Externí odkaz: